U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H23N5O3S.ClH.3H2O
Molecular Weight 516.011
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FILGOTINIB HYDROCHLORIDE

SMILES

O.O.O.Cl.O=C(NC1=NN2C(C=CC=C2C3=CC=C(CN4CCS(=O)(=O)CC4)C=C3)=N1)C5CC5

InChI

InChIKey=VLVWKOPMGYYNKV-UHFFFAOYSA-N
InChI=1S/C21H23N5O3S.ClH.3H2O/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25;;;;/h1-7,17H,8-14H2,(H,23,24,27);1H;3*1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H23N5O3S
Molecular Weight 425.504
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800032685 | http://www.glpg.com/docs/view/564327aec62e3-en | http://www.glpg.com/docs/view/5719315eea963-en

Filgotinib (GLPG0634) is a highly selective JAK1 inhibitor. GLPG0634 is a promising drug candidate for the future treatment of autoimmune and inflammatory disorders. It is in phase III clinical trials (initiated mid-2016) for the treatment of rheumatoid arthritis, Crohn's disease and ulcerative colitis. Most common adverse events observed were infections, gastrointestinal disorders and nervous system disorders.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2580 ng/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4.42 μg/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1160 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10200 ng × h/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
16.3 μg × h/mL
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4844 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.09 h
450 mg 1 times / day multiple, oral
dose: 450 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
5.68 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FILGOTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6
healthy, ADULT
n = 47
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 47
Sources: Page: p.6
Disc. AE: Skin rash...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 1, 2.1%)
Sources: Page: p.6
AEs

AEs

AESignificanceDosePopulation
Skin rash grade 1, 2.1%
Disc. AE
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6
healthy, ADULT
n = 47
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 47
Sources: Page: p.6
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 110 uM]
no [IC50 140 uM]
no [IC50 151.6 uM]
no [IC50 158 uM]
no [IC50 168 uM]
no [IC50 188 uM]
no [IC50 90 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >105.8 uM]
no [IC50 >170 uM]
no [IC50 >200 uM]
no [IC50 >200 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >224 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >300 uM]
no [IC50 >40 uM]
no [IC50 >50 uM]
no [IC50 >500 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >60 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >70.6 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no [IC50 >80 uM]
no
no
no
no
no
no
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
weak [IC50 >70.6 uM]
yes [IC50 10.9 uM]
yes [IC50 14.9 uM]
yes [IC50 5.21 uM]
yes [IC50 8.63 uM]
yes [IC50 8.7 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Daily dose range up to 200 mg
Route of Administration: Oral
Filgotinib inhibited IL-2– and IL-4–induced JAK1/JAK3/γc signaling and IFN-αB2–induced JAK1/TYK2 type II receptor signaling most potently. IC50 values ranged from 150 to 760 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:09:13 UTC 2023
Edited
by admin
on Sat Dec 16 08:09:13 UTC 2023
Record UNII
2CQ8Y0B8XQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FILGOTINIB HYDROCHLORIDE
USAN  
USAN  
Official Name English
FILGOTINIB HYDROCHLORIDE [USAN]
Common Name English
G146034_101
Code English
GLPG-0634
Code English
G-146034_101
Code English
CYCLOPROPANECARBOXAMIDE, N-(5-(4-((1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-, HYDROCHLORIDE, HYDRATE (1:1:3)
Systematic Name English
N-(5-(4-((1,1-DIOXO-.DELTA.6-THIOMORPHOLIN-4-YL)METHYL)PHENYL)(1 ,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)CYCLOPROPANECARBOXAMIDE MONOHYDROCHLORIDE TRIHYDRATE
Systematic Name English
FILGOTINIB HYDROCHLORIDE TRIHYDRATE
WHO-DD  
Common Name English
Filgotinib hydrochloride trihydrate [WHO-DD]
Common Name English
GLPG0634
Code English
Code System Code Type Description
EVMPD
SUB197230
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
FDA UNII
2CQ8Y0B8XQ
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
ChEMBL
CHEMBL3301607
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
CAS
1540859-07-1
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
NCI_THESAURUS
C166565
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
PUBCHEM
76963285
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
SMS_ID
100000182934
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
USAN
BC-111
Created by admin on Sat Dec 16 08:09:13 UTC 2023 , Edited by admin on Sat Dec 16 08:09:13 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY